Padda 2023 PDEis

Question 1

phosphodiesterase inhibitors are class medications used in the management and treatment of

Answer 1

chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), benign prostatic hyperplasia(BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), atopic dermatitis(AD), and neonatal apnea.

Question 2

MoA

Answer 2

In the class of medications that prevent cAMP and/or cGMP degradation, it exhibits smooth muscle relaxation, vasodilatory, and bronchodilatory effects.

Question 3

most common PDE5i for ED

Answer 3

sildenafil

Question 4

sildenafil originally used to treat

Answer 4

pulmonary arterial hypertension

Question 5

PDE5i approved to treat ED

Answer 5

1. sildenafil
2. vardenafil
3. avanafil
4. tadalafil

Question 6

which PDE5i is also approved for BPH

Answer 6

tadalafil

Question 7

Cilostazol class

Answer 7

PDE3i

Question 8

Cilostazol MoA

Answer 8

PDE-3 inhibitor that reversibly inhibits platelets from aggregation and is indicated to treat intermittent claudication from peripheral arterial disease(PAD)

Question 9

Dipyridamole class and use

Answer 9

PDE-3 inhibitor and is used for postoperative prophylaxis for thrombosis, but its action on the PDE-3 enzyme is relatively weak. Dipyridamole can also be a diagnostic tool as a pharmacologic nuclear stress test. Dypriadamole increases perfusion to the myocardium, revealing reversible and irreversible ischemic areas in the myocardial muscle

Question 10

milrinone class

Answer 10

PDE3

Question 11

amrinone class

Answer 11

PDE3i

Question 12

Milrinone and amrinone also inhibit PDE-3 enzymes, but

Answer 12

their actions target heart cells, increasing cAMP in the myocardium, and producing a positive inotropic effect. Both agents may be used short-term for decompensated heart failure as therapy for greater durations may precipitate ventricular arrhythmias.

Question 13

Roflumilast class

Answer 13

PDE4i

Question 14

Roflumilast MoA

Answer 14

acts on the target cells of lung tissue and is indicated for the treatment of reducing COPD exacerbations.

Question 15

crisabarole class

Answer 15

PDE4i

Question 16

Apremilast class

Answer 16

PDE4i

Question 17

Apremilast/crisaborole use

Answer 17

psoriasis, PA, aD

Question 18

Theophylline class

Answer 18

non-specific PDE4i

Question 19

Theophylline use

Answer 19

COPD (symptomatic relief)

Question 20

pentoxifylline class

Answer 20

xanthine analog; non-selective PDEi

Question 21

Pentoxifylline use

Answer 21

muscle pain caused by PAD

Question 22

anagrelide class

Answer 22

PDE3i

Question 23

anagrelide use

Answer 23

thrombocythemia caused by myeloproliferative disorders

Question 24

Caffeine class

Answer 24

PDEi (by one of its 3 MoAs; also a CNS stimulant and apnea treatment)

Question 25

which are approved for ED?

Answer 25

1. sildenafil 2. tadalafil 3. vardenafil 4. avanafil

Question 26

which are approved for BPH?

Answer 26

tadalafil

Question 27

which are approved for pulmonary arterial hypertension

Answer 27

sildenafil, tadalafil

Question 28

which are approved for psoriatic arthritis

Answer 28

apremilast

Question 29

which are approved for psoriasis

Answer 29

apremilast

Question 30

which are approved for COPD?

Answer 30

theophylline, roflumilast

Question 31

which are approved for PAD

Answer 31

cilostazol, pentoxifylline

Question 32

whihc are approved for postoperative thromboembolic prophylaxis?

Answer 32

dipyridamole

Question 33

which are approved for decompensated cardiac failure

Answer 33

milrinone, amrinone

Question 34

which are approved for AD?

Answer 34

crisaborole

Question 35

which are approved for thrombocythemia

Answer 35

anagrelide

Question 36

which are approved for neonatal apnea

Answer 36

caffeine citrate

Question 37

roflumilast AEs

Answer 37

Gastrointestinal symptoms: nausea, vomiting, diarrhea Weight loss Decreased appetite Headache Insomnia Dizziness Anxiety Worsening depression

Question 38

BBW CI: cilostazol

Answer 38

HF

Question 39

BBW CI: milrinone

Answer 39

should not be used for >48 hours for HF as can cause ventricular arrhythmias and result in death